The purpose of this study is to understand how the loss of kidney function affects study medicine (PF-07923568) in the body. People with some level of loss of kidney function may process PF-07923568 differently from healthy people. PF-07923568 is developed as a possible treatment for respiratory syncytial virus (RSV) infection. RSV is a common virus that affects the lungs and usually causes mild, cold-like symptoms. RSV can cause severe lung infections in infants, elderly, and adults with other serious medical conditions. This study is seeking participants who: * Have less than 25% difference in kidney function between 2 screening visits. * Meet the eGFR criteria for being assigned to groups. eGFR tells how well the kidney is filtering. * Are not on hemodialysis. Hemodialysis is a type of treatment that helps the body remove extra fluid and waste products from the blood when the kidneys are not able to. Participants will take the study medicine as capsules by mouth once at the study clinic. The participants will stay at the study clinic for about 5 days. During that time, the study team will monitor the participants. The study team will take some blood samples to test the level of PF-07923568. This will help us understand if some level of loss of kidney function will have an effect on the study medicine PF-07923568.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
16
A single dose of PF-07923568 administered orally as 4 capsules
Orlando Clinical Research Center
Orlando, Florida, United States
Genesis Clinical Research, LLC
Tampa, Florida, United States
Prism Research LLC dba Nucleus Network
Saint Paul, Minnesota, United States
Clinical Trials of Texas, LLC
San Antonio, Texas, United States
Clinical Trials of Texas, LLC dba Flourish Research
San Antonio, Texas, United States
Clinical Trials of Texas, LLC
San Antonio, Texas, United States
Maximum Observed Plasma Concentration (Cmax)
Time frame: Baseline through Day 5
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)
Time frame: Baseline through Day 5
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Time frame: Baseline through Day 5
Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)
Time frame: Baseline through Day 36
Number of Participants With Change From Baseline in Laboratory Tests Results
Time frame: Baseline through Day 5
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
Time frame: Baseline through Day 5
Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECGs)
Time frame: Baseline through Day 5
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.